The Impact of Rheumatoid Arthritis Treatments on the Modulation of Extracellular Vesicles and Other Biomarkers Involved in the Development of Lung Cancer (RAPTOR)
Patients with rheumatoid arthritis (RA) have an increased risk of lung cancer, potentially influenced by targeted therapies such as JAK inhibitors and biologics. Extracellular vesicles (EVs) are key mediators of intercellular communication and may carry biomarkers involved in oncogenesis. This study aims to compare EV concentration and molecular content in RA patients treated with different targeted therapies. The objective is to identify treatment-related differences in EV profiles that may contribute to lung cancer development and improve risk stratification.
研究概览
地位
条件
详细说明
RA is associated with an increased incidence of lung cancer, with recent evidence suggesting a differential risk according to targeted therapies. The biological mechanisms underlying this association remain unclear. EVs are circulating nanovesicles involved in immune regulation and tumor progression, carrying proteins and nucleic acids that may reflect disease and treatment effects. This prospective monocentric observational study will include RA patients treated with JAK inhibitors, abatacept, anti-TNF, or anti-IL-6 therapies. A single additional blood sample will be collected during routine care. EV concentration will be measured, and their protein and miRNA content analyzed using omics approaches. Functional assays will assess the impact of EVs on bronchial epithelial and lung cancer cell lines.The study aims to identify EV-based biomarkers associated with specific treatments and potentially linked to lung cancer risk.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名：Pascale Vergne-Salle, Professor
- 电话号码：05 55 05 55 55
- 邮箱：pascale.vergne-salle@chu-limoges.fr
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients receiving rheumatology care at Limoges University Hospital with diagnosis of RA established
描述
Inclusion Criteria:
- Patients receiving rheumatology care at Limoges University Hospital
- Aged 18 years or over
- Diagnosis of RA established in accordance with the 2010 ACR (American College of Rheumatology) / EULAR (European League Against Rheumatism) classification criteria
- Patients who have been treated with a JAK inhibitor, anti-TNF agent, abatacept or anti-IL-6 for at least 1 month
- Patients capable of expressing their refusal
- Patients with up-to-date health insurance cover
Exclusion Criteria:
- Pregnant or breastfeeding women
- Patients under a protective regime (guardianship, curatorship)
学习计划
研究是如何设计的？
设计细节
- 观测模型：COHORT
- 时间观点：PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Patients being treated in the rheumatology department at Limoges University Hospital who have been d
Collection of additional blood tubes during a routine blood test |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Plasma extracellular vesicle (EV) concentration at inclusion
大体时间：6 months
|
Extracellular vesicle concentration will be measured, and their protein and miRNA content analyzed using omics approaches. Functional assays will assess the impact of EVs on bronchial epithelial and lung cancer cell lines.The study aims to identify EV-based biomarkers associated with specific treatments and potentially linked to lung cancer risk. |
6 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.